Embecta Corp Intrinsic Value – EMBECTA CORP Announces Fourth Quarter Fiscal Year 2023 Earnings of USD 281.9 Million, Up 2.7% Year-on-Year
December 17, 2023
🌥️Earnings Overview
On November 21 2023, EMBECTA CORP ($NASDAQ:EMBC) reported their results for the fourth quarter of fiscal year 2023, which concluded on September 30 2023. Total revenue for the quarter was USD 281.9 million, indicating a 2.7% rise compared to the same period of the previous year. Furthermore, net income was USD 6.0 million, representing a 134.9% increase from the same quarter the year before.
Analysis – Embecta Corp Intrinsic Value
GoodWhale has conducted an analysis of EMBECTA CORP‘s financials, calculating the fair value of its share to be around $31.0. This was calculated using our proprietary Valuation Line. However, the stock is currently traded at $17.1, representing a significant undervaluation of 44.8%. This indicates that there is potential for investors to benefit from buying the stock at its current low price. As such, investors may wish to research further into EMBECTA CORP’s financials to gain a more accurate understanding of its true value and potential for growth. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Embecta Corp. More…
| Total Revenues | Net Income | Net Margin |
| 1.12k | 70.4 | 6.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Embecta Corp. More…
| Operations | Investing | Financing |
| 67.7 | -26.5 | -48.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Embecta Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.21k | 2.04k | -14.33 |
Key Ratios Snapshot
Some of the financial key ratios for Embecta Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1.1% | -22.8% | 19.0% |
| FCF Margin | ROE | ROA |
| 3.7% | -16.3% | 10.9% |
Peers
The company was founded in 1980 and is headquartered in New York, NY. Embecta Corp‘s products include prescription drugs for the treatment of cardiovascular disease, diabetes, and cancer. The company’s competitors include Uluru Inc, RxSight Inc, and Modalis Therapeutics Corp.
– Uluru Inc ($OTCPK:ULUR)
RxSight Inc is a medical device company that develops and commercializes innovative ophthalmic implants that allow ophthalmologists to more precisely treat complex retinal diseases. As of 2022, the company has a market capitalization of 318.4 million and a return on equity of -31.3%.
– RxSight Inc ($NASDAQ:RXST)
Modalis Therapeutics Corp is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and other diseases. The company has a market cap of 11.21B as of 2022 and a return on equity of -13.14%. Modalis Therapeutics Corp is headquartered in New York, New York.
Summary
EMBECTA CORP recently reported strong fourth quarter earnings results for the fiscal year 2023, with total revenue of USD 281.9 million and net income of USD 6.0 million. The reported revenue growth of 2.7% year-over-year and the 134.9% year-over-year rise in net income was a welcome surprise for investors, and the stock price reacted positively to the news. Overall, the earnings suggest that EMBECTA CORP is in a strong financial position, and may be an attractive investment opportunity for investors.
